Clinical Scorecard: Prospective Analysis of Prognostic Factors in Brain Metastases Among Patients with Gastrointestinal Cancers: Findings from the METACER National Cohort Study
At a Glance
Category
Detail
Condition
Brain metastases (BM) in gastrointestinal (GI) cancers
Key Mechanisms
Metastatic spread to brain from GI primary tumors, influenced by tumor site, number and size of lesions, and disease prognosis
Target Population
Patients with colorectal cancer (CRC) and esogastric cancer (EGC) with synchronous or metachronous brain metastases
Care Setting
Multicentric French centers with prospective data collection
Key Highlights
BM incidence in GI cancers is rare but may be underdiagnosed without systematic brain imaging.
Median overall survival (OS) after BM diagnosis in GI cancers ranges from 2.0 to 8.7 months.
Prognostic factors such as number of brain lesions, performance status, surgical treatment, and chemotherapy influence OS.
Guideline-Based Recommendations
Diagnosis
Histological confirmation or imaging diagnosis without alternative explanation for BM.
Systematic brain imaging recommended to detect BM in metastatic GI cancer patients.
Management
Treatment decisions depend on primary tumor site, number and size of BM lesions, lesion localization, and overall prognosis.
Standard care for resectable BM in lung, breast, and melanoma includes surgery followed by radiotherapy or radiosurgery; GI cancer BM management is not standardized and relies on multidisciplinary approaches.
Consider surgery and chemotherapy as factors associated with prolonged OS.
Monitoring & Follow-up
Use RECIST 1.1 criteria for evaluating progression-free survival (PFS) and brain progression.
Monitor overall survival from primary tumor diagnosis to BM diagnosis and after BM treatment.
Risks
Poor prognosis with median OS ranging 2.0 to 8.7 months post BM diagnosis.
Potential underdiagnosis of BM without systematic brain screening.
Patient & Prescribing Data
130 patients with BM from GI cancers (105 CRC, 25 EGC), median age 66 years, 64.4% female.
16.2% did not receive chemotherapy before BM diagnosis; lines of chemotherapy data incomplete; surgical treatment and chemotherapy associated with improved survival.
Clinical Best Practices
Prospective collection of clinical data to identify prognostic factors is essential for treatment decision-making.
Multidisciplinary management tailored to tumor type, BM characteristics, and patient performance status.
Incorporate systematic brain imaging in metastatic GI cancer patients to improve BM detection.
Use prognostic factors such as number of brain lesions, WHO performance status, and treatment modalities to guide therapy.
by Violaine Randrian, Fabienne Portales, Olivier Bouché, Simon Thezenas, Benoist Chibaudel, May Mabro, Eric Terrebonne, Claire Garnier-Tixidre, Christophe Louvet, Thierry André, Thomas Aparicio, Olivier Dubreuil, Gregoire Bouché, Marc Ychou, David Tougeron
